| Recent advances in cardiovascular risk reduction: implications of ONTARGET. | |
| | |
MedLine Citation:
|
PMID: 19409352 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Renin-angiotensin-aldosterone system (RAAS) overactivity is associated with increased cardiovascular risk, a finding that may be explained by the key role of the RAAS in stimulating vascular and cardiac remodeling. Inhibition of RAAS activity with the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has been shown to reduce cardiovascular mortality in patients with heart failure. ACE inhibitors have also been shown to reduce the incidence of stroke, myocardial infarction (MI), and heart failure in high-risk patients without heart failure. These findings led to the evaluation of the ARB telmisartan versus the ACE inhibitor ramipril in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), a cardioprotection trial conducted in high-risk patients without left ventricular dysfunction or heart failure. The results of this trial showed that the ACE inhibitor ramipril and the ARB telmisartan are equally effective in reducing the incidence of cardiovascular death, MI, stroke, and hospitalization for heart failure in patients without heart failure or left ventricular dysfunction but at high risk for cardiovascular disease (CVD). These results confirm that RAAS inhibition, using ACE inhibitors or ARBs, is an effective approach to reducing cardiovascular mortality and morbidity in patients without heart failure who are at high risk for CVD. |
| | |
Authors:
|
Robert Guthrie |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Clinical cornerstone Volume: 9 Suppl 3 ISSN: 1098-3597 ISO Abbreviation: Clin Cornerstone Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-05-04 Completed Date: 2009-11-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9816002 Medline TA: Clin Cornerstone Country: United States |
Other Details:
|
Languages: eng Pagination: S18-26 Citation Subset: IM |
Affiliation:
|
Department of Emergency Medicine, The Ohio State University Columbus, Ohio 43212, USA. guthrie.1@osu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Antihypertensive Agents / therapeutic use* Benzimidazoles / therapeutic use* Benzoates / therapeutic use* Cardiovascular Diseases / epidemiology, prevention & control* Clinical Trials as Topic Drug Therapy, Combination Humans Hypertension / drug therapy* Ramipril / therapeutic use* Risk Reduction Behavior |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 144701-48-4/telmisartan; 87333-19-5/Ramipril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combined use of miniscrews and clear appliances for the treatment of bialveolar protrusion without c...
Next Document: The management and treatment of hypertension.